ABDX - Ticker AI Digest

Abingdon Health Plc 📰 1
TradingFloor AI GO VIP Login

Digested News

Today's Catalysts (ABDX) 1
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
AI 0
No items for this category on selected date.
Acquisitions 0
No items for this category on selected date.
Agreement 0
No items for this category on selected date.
Approvals 0
No items for this category on selected date.
Authorisation 0
No items for this category on selected date.
Awards 0
No items for this category on selected date.
BTC 0
No items for this category on selected date.
Blockchain 0
No items for this category on selected date.
Breakthrough 0
No items for this category on selected date.
BuyBack 0
No items for this category on selected date.
Cancellations 0
No items for this category on selected date.
CashOffer 0
No items for this category on selected date.
Collaborate 0
No items for this category on selected date.
ContractWin 0
No items for this category on selected date.
Covid-19 0
No items for this category on selected date.
Deals 0
No items for this category on selected date.
Diamond 0
No items for this category on selected date.
DirectorDealing 0
No items for this category on selected date.
Discovery 0
No items for this category on selected date.
Exceeded 0
No items for this category on selected date.
FCA 0
No items for this category on selected date.
FDA 0
No items for this category on selected date.
Grants 0
No items for this category on selected date.
InvestmentPlan 0
No items for this category on selected date.
JV 0
No items for this category on selected date.
Launch 2
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
ABDX 06:59
Abingdon Health Plc
Launch of Retail Offer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a UK-based med-tech company specializing in rapid diagnostic <mark style="background-color:yellow">test</mark>s and contract development and manufacturing (CDMO) services, announced a retail offer of new ordinary shares to raise up to £200,000. The offer, priced at 6 pence per share, is open to existing retail shareholders in the United Kingdom, with a minimum subscription of £100 per investor. The retail offer runs from October 14 to October 16, 2025, and is part of a larger fundraising effort that includes a placing of shares to institutional investors, aiming to raise up to £3.34 million in total.
The funds raised will support the expansion of Abingdon Healths lateral flow manufacturing capacity in the USA and provide working capital for executing larger CDMO contracts. The retail offer is managed through the BookBuild platform, with Zeus Capital Limited acting as the retail offer coordinator. Shares issued under the retail offer will rank equally with existing ordinary shares and are expected to be admitted to trading on October 31, 2025.
The offer is subject to specific eligibility criteria, including residency in the UK and existing share ownership in the company. It is not available to US persons or in jurisdictions where it would violate local laws. The company emphasizes the risks associated with the investment and advises investors to seek independent advice. The announcement also includes important notices regarding regulatory compliance, product governance, and disclaimers related to forward-looking statements and investment risks.
Litigation 0
No items for this category on selected date.
NewContract 1
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
Offers 0
No items for this category on selected date.
Offtake 0
No items for this category on selected date.
Orders 0
No items for this category on selected date.
Partner 0
No items for this category on selected date.
Patents 0
No items for this category on selected date.
Placing 3
ABDX 06:01
Abingdon Health Plc
Result of Retail Offer
ABDX 06:48
Abingdon Health Plc
Result of Placing and Notice of GM
ABDX 16:05
Abingdon Health Plc
Proposed Placing and Retail Offer
Positive 0
No items for this category on selected date.
Proposals 0
No items for this category on selected date.
Reports 0
No items for this category on selected date.
Results 1
ABDX 06:01
Abingdon Health Plc
Notice of Results
Significant 0
No items for this category on selected date.
Speculation 0
No items for this category on selected date.
Strategic 0
No items for this category on selected date.
Suspension 0
No items for this category on selected date.
TR1 2
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
Takeover 0
No items for this category on selected date.
Understanding 0
No items for this category on selected date.
Updates 0
No items for this category on selected date.
Vaccine 0
No items for this category on selected date.
Wins 0
No items for this category on selected date.
Worth 0
No items for this category on selected date.
All Market News (Last 30 Days) 10
ABDX 06:01
Abingdon Health Plc
c.US$2m multiplex diagnostic test contract win
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has secured a **c.US$2 million contract** with a US-based company for the development, scale-up, and technical transfer of a **semi-quantitative, multiplex lateral flow test system**. The 24-month project will be executed under a Master Service Agreement (MSA) and conducted at Abingdon Health’s Madison, Wisconsin facilities. This win highlights the strength of Abingdon Health’s **Contract Development and Manufacturing Organisation (CDMO)** services, which support customers from concept to commercial success. The contract underscores the company’s expanded U.S. manufacturing capabilities, bolstered by a recent £3.2 million fundraise, and its ability to meet growing demand from U.S.-based clients. Dr. Chris Hand, Executive Chairman, emphasized the value of Abingdon’s dual U.S. and U.K. sites and the versatility of lateral flow technology in measuring multiple analytes semi-quantitatively. The announcement reinforces Abingdon Health’s position as a comprehensive CDMO provider in the med-tech sector.
ABDX 06:01
Abingdon Health Plc
Launch of seaweed-based lateral flow housings
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a leading developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s, has launched seaweed-based lateral flow test (LFT) housings as a sustainable alternative to traditional plastic housings. This innovation aims to reduce the significant plastic waste generated by the over 2 billion LFTs used annually worldwide. The company has partnered exclusively with Symbio Technologies Ltd (SymbioTex) to supply compostable, bio-based material derived from red seaweed, which can be molded using standard injection techniques. Prototypes have been developed for both standard and mid-stream urine sample formats, including pregnancy tests. The seaweed-based housings maintain the functionality of traditional tests while offering an eco-friendly solution. This initiative aligns with Abingdon Health’s commitment to sustainability and leverages renewable resources without requiring new manufacturing infrastructure. The launch underscores the company’s role in addressing environmental concerns in the med-tech industry.
ABDX 15:59
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Holding(s) in Company
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
TR1 Buy
ABDX 06:01
Abingdon Health Plc
Notice of Results
ABDX 08:44
Abingdon Health Plc
Result of Meeting and TVR
ABDX 06:01
Abingdon Health Plc
Result of Retail Offer
ABDX 06:59
Abingdon Health Plc
Launch of Retail Offer
Open AI Digest
Return to today’s catalyst cards, chart beacons and AI charts.
**Summary**
Abingdon Health plc, a UK-based med-tech company specializing in rapid diagnostic <mark style="background-color:yellow">test</mark>s and contract development and manufacturing (CDMO) services, announced a retail offer of new ordinary shares to raise up to £200,000. The offer, priced at 6 pence per share, is open to existing retail shareholders in the United Kingdom, with a minimum subscription of £100 per investor. The retail offer runs from October 14 to October 16, 2025, and is part of a larger fundraising effort that includes a placing of shares to institutional investors, aiming to raise up to £3.34 million in total.
The funds raised will support the expansion of Abingdon Healths lateral flow manufacturing capacity in the USA and provide working capital for executing larger CDMO contracts. The retail offer is managed through the BookBuild platform, with Zeus Capital Limited acting as the retail offer coordinator. Shares issued under the retail offer will rank equally with existing ordinary shares and are expected to be admitted to trading on October 31, 2025.
The offer is subject to specific eligibility criteria, including residency in the UK and existing share ownership in the company. It is not available to US persons or in jurisdictions where it would violate local laws. The company emphasizes the risks associated with the investment and advises investors to seek independent advice. The announcement also includes important notices regarding regulatory compliance, product governance, and disclaimers related to forward-looking statements and investment risks.
ABDX 06:48
Abingdon Health Plc
Result of Placing and Notice of GM
ABDX 16:05
Abingdon Health Plc
Proposed Placing and Retail Offer

AI Crunch

Single-Ticker AI Crunch
ABDX signal theatre built from scored market catalysts, automated AI forecasts, and live trigger logic.

This is the ticker-specific AI Crunch desk for Abingdon Health Plc. It compresses bullish and bearish catalyst scoring, best and worst AI forecast paths, and automated buy or sell trigger logic into one cockpit so users can judge conviction without hopping across screens.

Subscription Required Bullish vs Bearish Scoring AI Forecast Stack Buy / Sell Trigger Engine Catalyst Ledger
Create Account Member Login
Subscriber Unlock
Subscribe to unlock the full ABDX AI Crunch cockpit.

Subscription turns this tab into a live signal desk with bullish vs bearish machine scoring, AI forecast stack comparisons, buy and sell trigger logic, and the full catalyst ledger behind every scored catalyst row.

  • AI-scored market headlines with sentiment buckets and buzzword breakdowns.
  • Forecast leaders ranked by projected gain against current market price.
  • Advanced technical scans, AI forecast stacks, and predictive MACD inside the live stock terminal charts.
  • Single-ticker AI Crunch desks with buy or sell trigger logic and full catalyst ledgers.
  • Scored earnings shock board with predicted direction, sector pulse and catalyst narrative.
  • Fast market scan built for event-driven trading, not passive dashboards.
Subscribe to unlock the ticker-specific signal stack, sentiment gauges, forecast stage, and the full catalyst ledger for ABDX on 2025-11-10.

Fundamentals Matrix

Overall Fundamentals
Signal: Pending
Capital Strength
Signal: Pending
Float Liquidity
Signal: Pending
Short Pressure
Signal: Pending
Target Setup
Signal: Pending
Market Profile
Signal: Pending
Market Cap
21781004
Enterprise Value
4187469
Public Float
66.76
Broker Target
19
Shares Out
251077850
Long Interest
-
Short Interest
-
Exchange
LSE
Currency Code
GBX
ISIN
GB00BLF79J41
Market
LSE - AIM
Sector
Medical Equipment and Services
Float / Shares Ratio
-
Short vs Long Delta
-
EV / Market Cap
-

Financials Matrix

Overall Stability
Signal: Pending
Profitability
Signal: Pending
Debt & Cash
Signal: Pending
Valuation Risk
Signal: Pending
Forward Expectation
Signal: Pending
Dividend Safety
Signal: Pending
Divi Rate
-
Ex Divi
2009-01-01
Earnings Date
2026-04-01
Net Debt
-890000.0
Cash
1918000.0
EPS
-0.01
Net Income
-3415000.0
Revenue
8429000.0
Enterprise Value
4187469
Trailing PE
-
Forward PE
53.1915
Price Sales TTM
2.2755
Price Book MRQ
3.1878
EV Revenue
1.8102
EV EBITDA
-0.2499

Capital Radar

Capital Regime
—
Building signal blend...
Smart Money Tilt
—
Public vs institutions
Target Conviction
—
Broker coverage pulse
Insider Pressure
—
Director + TR1 flow
Last Held Position
-
Public Hands
-
Institutions
44.9753
Institutions As Of
2025-11-04
Avg Broker Target
-
Upside Vs Price
-
Purchase Director Dealing
0
Sale Director Dealing
0
Purchase TR1
6
Sale TR1
1
Broker Coverage Rows
0
Institution Holders Tracked
5
Public Vs Institutional Ownership (3D)
Top Institution Holders (Latest Per Holder)
Director Dealing Sentiment Flow
Broker Target Bias
Signal: Pending
Capital Momentum Matrix
Broker Targets Vs Price
Aggregated Institution Weight By Holder

Short Data - Last 30 Days

Nexus Pulse Engine

Overall Buy/Sell/Hold
Signal: Pending
Technical Composite
Signal: Pending
Financial Composite
Signal: Pending
Fundamental Composite
Signal: Pending
Short Pressure
Signal: Pending
Momentum Bias
Signal: Pending

Volatility Lab

ATR(14)
Realized Vol (20d)
Volume Spike Z

AI Charts

Today's Catalysts

1 live catalyst just hit ABDX.

The headlines landing in Digested News are now framed here as today's catalyst tape. Scroll the tab rail to Digested News or jump there instantly below.
Live Tape Data 2025-11-10 AI Charts Landing View
Scroll the tab rail to Digested News any time, or use the jump button to land straight on today's tape.
1 Today
Catalyst Pulse
Abingdon Health Plc has fresh news flow feeding the chart narrative.
AI Charts Studio
ABDX Price History
Live structure, automated forecasts, technical overlays and catalyst beacons in one chart workspace.
30 Day View Window 30D Data 2025-11-10 Open Preview Studio Brief
Chart Intelligence Suite
Swipe the timeframe, call the overlays, and keep the AI signal stack fused into one chart cockpit.
The mobile chart console is now framed as one connected surface so forecasting, structure, catalyst beacons and chart tools all sit inside the price workspace.

Automated signalling scans momentum shifts, crossovers and volatility breaks in real time. Automated AI forecasts map best, average and worst simulation paths forward, predictive MACD extends the momentum story, and catalyst beacons pin market-moving headlines directly onto price action so users can connect news, signals and structure without leaving the chart.

Automated Signalling Automated AI Forecasts Predictive MACD Catalyst Beacons Live Price Structure
TradingFloor AI Member Login
Indicators0
Technicals0
AI Forecast -21.43%
RSI Gauge
Price Change
AI Forecast